激素初治类风湿关节炎患者短期糖皮质激素剂量与疗程依赖的心血管事件风险
基于CorEvitas类风湿关节炎注册队列的回顾性分析纳入19 902例激素初治患者,评估起始糖皮质激素后短期内心血管事件风险。结果显示当前泼尼松等效日剂量≥5-9 mg及≥10 mg、近6个月累积剂量751-1100 mg及>1100 mg、用药时长>81天均与心血管事件风险升高相关,而日剂量0-4 mg及更低累积剂量和更短疗程未见风险增加。
要点
- 激素初治RA患者起始泼尼松等效日剂量≥5 mg即与心血管事件风险升高相关。
- 近6个月累积剂量>1100 mg或用药>81天者心血管事件风险显著增加。
- 日剂量≤4 mg及更低累积剂量和更短疗程未观察到心血管事件风险增加。
核心结论
- 在激素初治的RA患者中,起始糖皮质激素后短期(近6个月及1年)内,日剂量≥5 mg、较高累积剂量及较长用药时长与心血管事件风险升高相关。
- 日剂量≤4 mg、较低累积剂量及较短用药时长未观察到与心血管事件风险的关联。
研究设计与样本
- 基于CorEvitas(原Corrona)RA注册队列的观察性研究,纳入19 902例符合标准的激素初治RA患者。
- 采用Cox比例风险模型估计起始糖皮质激素后发生心血管事件的调整风险比(aHR),校正RA病程、传统心血管危险因素及时间变化协变量(CDAI、DMARDs使用、泼尼松等效剂量)。
- 糖皮质激素暴露评估当前日剂量、累积剂量及用药时长,采用近6个月和1年的滚动区间。
主要发现
- 共发生1106例心血管事件,发生率为1.66/100人年。
- 1年区间分析结果与6个月区间一致。
临床怎么用
- 对激素初治RA患者,应优先考虑泼尼松等效日剂量≤4 mg,以降低短期心血管事件风险。
- 需关注近6个月累积剂量和用药时长,避免累积剂量>751 mg或用药>81天。
- 启动激素治疗时应评估传统心血管危险因素并纳入风险分层。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Rheumatoid arthritis (RA), along with glucocorticoid use, is associated with cardiovascular disease. Cardiovascular safety of glucocorticoids in RA is controversial and may be related to dose and duration of use. We determined if initiating glucocorticoids in steroid-naive RA patients would increase cardiovascular event (CVE) risk in a dose and duration-dependent manner over short-term intervals. METHODS: Patients enrolled in CorEvitas (formerly Corrona) RA registry. Cox proportional-hazards models estimated adjusted HRs (aHR) for incident CVE in patients who initiated glucocorticoid treatment, adjusting for RA duration, traditional cardiovascular risk factors and time-varying covariates: Clinical Disease activity Index, disease-modifying antirheumatic drugs use and prednisone-equivalent use. Glucocorticoid use assessed current daily dose, cumulative dose and duration of use over rolling intervals of preceding 6 months and 1 year. RESULTS: 19 902 patients met criteria. 1106 CVE occurred (1.66/100 person-years). Increased aHR occurred at current doses of ≥5-9 mg 1.56 (1.18-2.06) and ≥10 mg 1.91 (1.31-2.79), without increased risk at 0-4 mg 1.04 (0.55-1.59). Cumulative dose over preceding 6 months showed increased aHR at 751-1100 mg 1.43 (1.04-1.98) and >1100 mg 2.05 (1.42-2.94), without increased risk at lower doses; duration of use over preceding 6 months exhibited increased aHR for >81 days of use 1.54 (1.08-2.32), without increased risk at shorter durations. One-year analyses were consistent. CONCLUSIONS: Over preceding 6-month and 1-year intervals, initiating glucocorticoids in steroid-naïve RA patients is associated with increased risk of CVE at daily doses ≥5 mg and increased cumulative dose and duration of use. No association with risk for CVE was found with daily prednisone of ≤4 mg or shorter cumulative doses and durations.
引用
- Ocon AJ, Reed G, Pappas DA, et al. Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis. Ann Rheum Dis. 2021. PMID: 34215644. doi:10.1136/annrheumdis-2021-220577
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。